Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marijo Otero-Lobato"'
Autor:
Marijo Otero‐Lobato, Adesoji Adeyemo, Michelle Higley, Kathleen G. Lomax, Anja Geldhof, Suzan Esslinger
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract Data on the use of golimumab (GLM) during pregnancy are limited. This study evaluated pregnancy outcomes in women treated with GLM during pregnancy. Cumulative data on GLM‐exposed pregnancies from the Company's global safety database (GSD)
Externí odkaz:
https://doaj.org/article/09f8486643174e988a35c2cb946ca532
Autor:
Suzan Esslinger, Linda Quinn, Sami Sampat, Marijo Otero-Lobato, Wim Noël, Anja Geldhof, Nicole Herijgers, Sarah-Jane Reeder
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 8, Iss 1, Pp 1-15 (2022)
Abstract Introduction In the European Union (EU), a Risk Management Plan (RMP) is submitted as part of the dossier for initial marketing authorization of a medicinal product or with an application involving a significant change to an existing marketi
Externí odkaz:
https://doaj.org/article/1dfec1e1580b49d5ab6ef74bb17fea62
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 10 (2019)
Background: The golimumab safety awareness study commenced in 2010 to measure, periodically, the awareness of golimumab prescriber healthcare professionals (HCPs) of specific risks associated with golimumab as well as awareness of the requirement to
Externí odkaz:
https://doaj.org/article/fd95f2845dcc4c7d8cc77a9b5817af33
Autor:
Suzan Esslinger, Linda Quinn, Sami Sampat, Marijo Otero-Lobato, Wim Noël, Anja Geldhof, Nicole Herijgers, Sarah-Jane Reeder
Publikováno v:
Journal of pharmaceutical health care and sciences. 8(1)
Introduction In the European Union (EU), a Risk Management Plan (RMP) is submitted as part of the dossier for initial marketing authorization of a medicinal product or with an application involving a significant change to an existing marketing author
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7dcde2718b596777c170ab12bc77e4d
https://pubmed.ncbi.nlm.nih.gov/35509028
https://pubmed.ncbi.nlm.nih.gov/35509028
Autor:
Najat Ziyadeh, Suzan Esslinger, W. Noel, John D. Seeger, Soumya D. Chakravarty, A. Geldhof, Marijo Otero-Lobato, Yiting Wang
Publikováno v:
Clinical Drug Investigation
Background and Objective Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eef1d2fe66996559a336976c8ae25d4
https://pubmed.ncbi.nlm.nih.gov/32779120
https://pubmed.ncbi.nlm.nih.gov/32779120
Publikováno v:
Journal of Crohn's and Colitis. 14:S500-S501
Background Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for several rheumatological indications and ulcerative colitis (UC). To characterise pregnancy outcomes in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6ab444e3e0aa6e42153686a020520ce
https://doi.org/10.1093/ecco-jcc/jjz203.727
https://doi.org/10.1093/ecco-jcc/jjz203.727
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 10 (2019)
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety
Background: The golimumab safety awareness study commenced in 2010 to measure, periodically, the awareness of golimumab prescriber healthcare professionals (HCPs) of specific risks associated with golimumab as well as awareness of the requirement to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbfd86b3106163d010756782f1406590
https://doaj.org/article/fd95f2845dcc4c7d8cc77a9b5817af33
https://doaj.org/article/fd95f2845dcc4c7d8cc77a9b5817af33
Publikováno v:
Annals of the Rheumatic Diseases. 79:992.2-992
Background:Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for several rheumatologic indications and ulcerative colitis (UC).Objectives:To characterize pregnancy outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cc90bd9ba2fadc1697d6285335eec60
https://doi.org/10.1136/annrheumdis-2020-eular.2796
https://doi.org/10.1136/annrheumdis-2020-eular.2796